BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 8749599)

  • 1. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
    van der Does J; Exalto N; Dieben T; Bennink HC
    Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian function during low-dose oral contraceptive use.
    Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
    Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enlarged follicles in women using oral contraceptives.
    Broome M; Clayton J; Fotherby K
    Contraception; 1995 Jul; 52(1):13-6. PubMed ID: 8521709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives.
    Hamerlynck JV; Vollebregt JA; Doornebos CM; Muntendam P
    Contraception; 1987 Mar; 35(3):199-205. PubMed ID: 2956054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.
    Wenzl R; Bennink HC; van Beek A; Spona J; Huber J
    Fertil Steril; 1993 Oct; 60(4):616-9. PubMed ID: 8405513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound evaluation of ovarian activity under oral contraceptives.
    Hoogland HJ; Skouby SO
    Contraception; 1993 Jun; 47(6):583-90. PubMed ID: 8334892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
    Gaspard UJ; Deville JL; Dubois M
    Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
    Kuhl H; Gahn G; Romberg G; März W; Taubert HD
    Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.